Melissa Starovasnik Sells 1,000 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) Director Melissa Starovasnik sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the sale, the director directly owned 25,722 shares in the company, valued at approximately $1,311,822. This trade represents a 3.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Price Performance

Twist Bioscience stock remained flat at $50.21 during trading on Friday. 970,699 shares of the company were exchanged, compared to its average volume of 1,121,877. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $57.88. The stock has a market capitalization of $3.08 billion, a PE ratio of -39.23 and a beta of 2.20. The firm has a 50-day moving average of $46.84 and a 200 day moving average of $37.12.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm had revenue of $103.70 million during the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience’s revenue was up 16.9% on a year-over-year basis. On average, equities analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analysts Set New Price Targets

TWST has been the topic of a number of analyst reports. Evercore raised their price target on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Barclays increased their price objective on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, February 3rd. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Finally, Robert W. Baird set a $50.00 price target on Twist Bioscience in a report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.50.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP acquired a new position in Twist Bioscience in the third quarter valued at $28,000. Smartleaf Asset Management LLC lifted its holdings in shares of Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares during the last quarter. Strategic Advocates LLC boosted its position in shares of Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares during the period. SBI Securities Co. Ltd. boosted its position in shares of Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after purchasing an additional 571 shares during the period. Finally, National Bank of Canada FI purchased a new position in Twist Bioscience during the 3rd quarter worth approximately $46,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.